Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 9/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 8/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 8/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.67 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.67 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.67 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.67 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.67 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.67 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.67 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.67 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.67 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.67 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30905563 | 1.00 | GRIA2 (1.00) | GRIA2GRIA1GRIA3GRIA4MAPT | |
| SCHEMBL3686717 | 0.83 | GRIA2 (0.71) | GRIA2GRIA1GRIA3GRIA4MAPT | |
| Dnqx SCHEMBL594575 | 0.81 | GRIA2 (1.00) | GRIA2GRIA1GRIA3GRIA4MAPT | |
| SCHEMBL9971326 | 0.79 | GRIA1 (0.63) | GRIA2GRIA1GRIA3GRIA4MAPT | |
| SCHEMBL9393185 | 0.78 | GRIA1 (0.63) | GRIA2GRIA1GRIA3GRIA4MAPT | |
| SCHEMBL12619187 | 0.78 | GRIA1 (0.63) | GRIA2GRIA1GRIA3GRIA4MAPT | |
| SCHEMBL25389388 | 0.76 | MAPT (0.61) | GRIA2GRIA1GRIA3GRIA4MAPT | |
| SCHEMBL7417792 | 0.74 | GRIA1 (0.56) | GRIA2GRIA1GRIA3GRIA4MAPT | |
| SCHEMBL9746827 | 0.73 | GRIA1 (0.63) | GRIA2GRIA1GRIA3GRIA4MAPT | |
| SCHEMBL7482757 | 0.73 | GRIA2 (0.74) | GRIA2GRIA1GRIA3GRIA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025065271-A1 | METHODS AND DEVICES FOR TREATING DEPRESSION | Liangzhu Laboratory (CN) | 2025-04-03 | — | — | WO | claimed |
| WO-2023196234-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310380-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| US-20220251627-A1 | COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF | ZYMO RESEARCH CORPORATION (US) | 2022-08-11 | — | — | US | claimed |
| EP-3989722-A1 | COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF | Zymo Research Corporation (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2026101998-A1 | THREE-DIMENSIONAL MICROINSTRUMENTED NEURAL NETWORK DEVICE | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12600985-B2 | Compositions and methods for controlling production of polypeptides in cells | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-12576042-B2 | Methods and compositions for treating neurological conditions | LIPTON STUART A (US) | 2026-03-17 | — | — | US | disclosed |
| US-12515077-B2 | Devices and methods based on ultrasounds for restoring vision or any other brain function | SORBONNE UNIVERSITE (GR) | 2026-01-06 | — | — | US | disclosed |
| US-20250345365-A1 | TREATMENT OF NEURONAL DISEASES | CENTER FOR EXCELLENCE IN BRAIN SCIENCE AND INTELLIGENCE TECH CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250340884-A1 | ANTISENSE OLIGOMERS AGAINST MONOAMINE OXIDASE B AND USE THEREOF | INST BASIC SCIENCE (KR) | 2025-11-06 | — | — | US | disclosed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000054772-A1 | AMYOTROPIC LATERAL SCLEROSIS TREATMENT WITH A COMBINATION OF RILUZOLE AND AN AMPA RECEPTOR ANTAGONIST | AVENTIS PHARMA S.A. (FR) | 2000-09-21 | — | — | WO | disclosed |
| US-5977107-A | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | COCENSYS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | GRIA2 1365/4885GRIA1 1312/4885GRIA3 1422/4885 |
| US-12600985-B2 | Compositions and methods for controlling production of polypeptides in cells | FOSB, CALCB, CHERP | GRIA2 595/4885GRIA1 1173/4885GRIA3 759/4885 |
| US-12576042-B2 | Methods and compositions for treating neurological conditions | NCSTN, GRIN2C, NOTCH1 | GRIA2 160/4885GRIA1 356/4885GRIA3 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.